Evidence map›Paper›PMID 39020004›Full record

ArticleScientific reports2024

A multicenter study of long-term outcomes of relapsing polychondritis in Iran.

Mehdi Jafarpour, Maryam Saberivand, Maryam Saemi, Maryam Sahebari, Seyedmostafa Seyedmardani, Mansour Salesi, Sarah Hosseinpoor, Tahereh Faezi, Kamal Esalatmanesh, Mehrzad Hajialilo and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mehdi JafarpourConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
Maryam SaberivandConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
Maryam SaemiConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
Maryam SahebariRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyedmostafa SeyedmardaniDepartment of Internal Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Mansour SalesiDepartment of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Sarah HosseinpoorDepartment of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Tahereh FaeziRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Kamal EsalatmaneshDepartment of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Mehrzad HajialiloConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
Sousan KolahiConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
Zahra MyrfeiziDepartment of Internal Medicine, Mashad University of Medical Sciences, Mashhad, Iran.
Alireza KhabbaziConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran. dr_khabbazi@yahoo.com.

Funding

Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences CTDRC.1402.33
6 · The paper itself

Abstract

Relapsing polychondritis (RP) is a systemic immune mediated disease characterized by recurrent episodes of inflammation in various cartilage-rich areas. RP may cause extensive tissue destruction and is associated with significant morbidity and mortality. In this multicenter study, we considered the remission status and long-term outcomes of RP in patients who were followed-up in six referral rheumatology centers in Iran. Outcomes of disease was assessed by remission status and RP induced damage. A total of 29 patients with RP were examined for enrollment in the study, and 26 patients with a minimum follow-up period of 6 months were included in the RP outcome analysis. Median time to control of symptoms and sustained remission were 5 and 23 weeks, respectively. Prednisolone was discontinued in 8 (30.8%) patients and medication-free remission was achieved in 7 (23.1%) patients. Regarding the disease course, 34.6% of patients had a relapsing-remitting course, 42.3% had a monophasic course, and 23.1% had an always-active course. Despite extensive treatment with immunosuppressive medications, RP induced damage was developed in 21 (80.8%) patients. Ear deformity and osteoporosis were the most common RP induced damage. Long-term remission and medications-free remission in RP is accessible. However, RP related damage occur in majority of patients.

Indexed as

Polychondritis, RelapsingAdultAgedFemaleFollow-Up StudiesHumansImmunosuppressive AgentsIranMaleMiddle AgedPrednisoloneRemission InductionTreatment OutcomeYoung AdultImmunosuppressive AgentsPrednisoloneDisease modifying antirheumatic drugs (DMARDs)ImmunosuppressantsRelapseRelapsing polychondritisRemission

Identifiers

PMID39020004
PMCPMC11255289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.